<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between March 1983 and December 1992, we performed 178 allogeneic BMTs for patients with hematopoietic stem cell disorders: 48 <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 27 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL), 40 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 55 severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA), 6 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 1 non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 1 hybrid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-five of 48 AML are in disease-free survival (DFS) </plain></SENT>
<SENT sid="2" pm="."><plain>Fifteen of 27 ALL are in unmaintained remission </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty-four of 40 <z:mp ids='MP_0005481'>CML</z:mp> are in DFS </plain></SENT>
<SENT sid="4" pm="."><plain>Forty-four out of 55 SAA patients are alive and well </plain></SENT>
<SENT sid="5" pm="."><plain>Comparing the survival between standard (&lt; or = CR1: 21 of 31 (68%)) and high risk (&gt; or = CR2: 4 of 17 (24%)) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, our data suggest that the preparative regimen for high risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was not potent enough to eradicate the <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> in advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Although our cases are limited and the follow-up period is short, the result of ALL (overall: 56%, standard risk (adult &lt; or = CR1, children &lt; or = CR2: 10 of 14 (71%) and high risk (adult &gt; or = CR2, children &gt; CR2): 5 of 13 (38%)) and <z:mp ids='MP_0005481'>CML</z:mp> (overall: 60%; CP: 19 of 27 (70%), AP or BC: 5 of 13 (38%)) are promising </plain></SENT>
<SENT sid="7" pm="."><plain>The probability of 5 year survival of SAA was 80 +/- 4 years.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>